NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure
Mirikizumab is now recommended by NICE for routine NHS use [...]
The National Institute for Health and Care Excellence (NICE) has [...]
UK-based Alchemab Therapeutics has signed a landmark licensing agreement with [...]
Partnership aims to accelerate development using computational drug design Creyon [...]